Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

1.

Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.

Parikh SA, Wierda WG.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10 Suppl 1:S27-33. doi: 10.3816/CLML.2010.s.004. Review.

PMID:
20529805
[PubMed - indexed for MEDLINE]
2.

Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.

Robak T, Lech-Maranda E, Robak P.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132. Review.

PMID:
20942624
[PubMed - indexed for MEDLINE]
3.

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.

Keating GM.

Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000. Review.

PMID:
20614951
[PubMed - indexed for MEDLINE]
4.

Emerging information on the use of rituximab in chronic lymphocytic leukemia.

Keating MJ, O'Brien S, Albitar M.

Semin Oncol. 2002 Feb;29(1 Suppl 2):70-4. Review.

PMID:
11842391
[PubMed - indexed for MEDLINE]
5.

Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.

O'Brien S, Osterborg A.

Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):361-8. doi: 10.3816/CLML.2010.n.069. Review.

PMID:
21030349
[PubMed - indexed for MEDLINE]
6.

Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.

Hillmen P.

Semin Oncol. 2004 Feb;31(1 Suppl 2):22-6. Review.

PMID:
15042531
[PubMed - indexed for MEDLINE]
7.

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

Cheson BD.

J Clin Oncol. 2010 Jul 20;28(21):3525-30. doi: 10.1200/JCO.2010.27.9836. Epub 2010 May 10. Review.

PMID:
20458041
[PubMed - indexed for MEDLINE]
8.

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.

J Clin Oncol. 2010 Apr 1;28(10):1756-65. doi: 10.1200/JCO.2009.26.4556. Epub 2010 Mar 1.

PMID:
20194844
[PubMed - indexed for MEDLINE]
9.

Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.

Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A.

Ann N Y Acad Sci. 2009 Sep;1173:865-73. doi: 10.1111/j.1749-6632.2009.04803.x. Erratum in: Ann N Y Acad Sci. 2010 Aug;1204:198. Eliezer, Rachmilewitz [corrected to Rachmilewitz, Eliezer A]; Ami, Schattner [corrected to Schattner, Ami].

PMID:
19758239
[PubMed - indexed for MEDLINE]
10.

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.

Jain P, O'Brien S.

Expert Opin Biol Ther. 2013 Feb;13(2):169-82. doi: 10.1517/14712598.2012.735655. Epub 2012 Dec 21. Review.

PMID:
23256681
[PubMed - indexed for MEDLINE]
11.

Ofatumumab, a human anti-CD20 monoclonal antibody.

Osterborg A.

Expert Opin Biol Ther. 2010 Mar;10(3):439-49. doi: 10.1517/14712590903586239. Review.

PMID:
20109133
[PubMed - indexed for MEDLINE]
12.

First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.

Hainsworth JD.

Semin Oncol. 2003 Feb;30(1 Suppl 2):9-15. Review.

PMID:
12652459
[PubMed - indexed for MEDLINE]
13.

Current and emerging treatments for chronic lymphocytic leukaemia.

Robak T, Jamroziak K, Robak P.

Drugs. 2009;69(17):2415-49. doi: 10.2165/11319270-000000000-00000.

PMID:
19911856
[PubMed - indexed for MEDLINE]
14.

Rituximab in B-cell chronic lymphocytic leukemia.

Lin TS, Lucas MS, Byrd JC.

Semin Oncol. 2003 Aug;30(4):483-92. Review.

PMID:
12939717
[PubMed - indexed for MEDLINE]
15.

Rituximab in chronic lymphocytic leukemia.

Jaglowski SM, Byrd JC.

Semin Hematol. 2010 Apr;47(2):156-69. doi: 10.1053/j.seminhematol.2010.01.005. Review.

PMID:
20350663
[PubMed - indexed for MEDLINE]
16.

Rituximab in chronic lymphocytic leukemia.

James DF, Kipps TJ.

Adv Ther. 2011 Jul;28(7):534-54. doi: 10.1007/s12325-011-0032-2. Epub 2011 Jul 2. Review.

PMID:
21725721
[PubMed - indexed for MEDLINE]
17.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group.

Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.

PMID:
20888994
[PubMed - indexed for MEDLINE]
18.

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.

Pickartz T, Ringel F, Wedde M, Renz H, Klein A, von Neuhoff N, Dreger P, Kreuzer KA, Schmidt CA, Srock S, Schoeler D, Schriever F.

Exp Hematol. 2001 Dec;29(12):1410-6.

PMID:
11750099
[PubMed - indexed for MEDLINE]
19.

Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma.

Keating GM.

BioDrugs. 2011 Feb 1;25(1):55-61. doi: 10.2165/11206980-000000000-00000.

PMID:
21222497
[PubMed]
20.

Monoclonal antibodies in the treatment of chronic lymphoid leukemias.

Robak T.

Leuk Lymphoma. 2004 Feb;45(2):205-19. Review.

PMID:
15101704
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk